Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats
- 28 October 2003
- journal article
- website
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 33 (11) , 1006-1012
Abstract
Background Portal hypertension in cirrhosis is the result of increased intrahepatic vascular resistance to portal outflow as well as increased portal tributary blood flow. The angiotensin II type 1 receptor antagonist losartan has been suggested as a portal pressure‐lowering drug in patients with cirrhosis. Aim To investigate the systemic and splanchnic haemodynamic effects of different doses of losartan. Methods In 35 anaesthetized rats with secondary biliary cirrhosis, 3, 10 or 30 mg of losartan kg−1 or solvent were administered intravenously. Ten sham‐operated rats served as controls. Mean arterial pressure and portal pressure were measured by catheters in the femoral artery or portal vein. Systemic and splanchnic haemodynamics and mesenterico‐systemic shunt rate were determined by the coloured microsphere method. Results Losartan reduced portal pressure (sham: 9·1 ± 0·4. cirrhosis: 19·3 ± 1·1, after 3 mg kg−1 of losartan 16·4 ± 0·4, after 10 mg kg−1 of losartan 15·6 ± 0·6, after 30 mg kg−1 of losartan 14·9 ± 0·6 mmHg) without reducing portal sinusoidal resistance. However, in cirrhotic rats it reduced portal tributary blood flow (sham: 4·3 ± 0·6. cirrhosis: 8·6 ± 1·4, after 3 mg kg−1 of losartan 3·8 ± 0·7, after 10 mg kg−1 of losartan 4·7 ± 0·5, after 30 mg kg−1 of losartan 5·9 ± 0·9 mmHg). This was owing either to an increase in splanchnic vascular resistance at the 3 mg kg−1 dose or to a reduction in the splanchnic perfusion‐pressure gradient secondary to a reduction in mean arterial pressure at the 10 and 30 mg kg−1 doses (mean arterial pressure: sham: 109·7 ± 4·8. cirrhosis: 109·4 ± 2·8, after 3 mg kg−1 of losartan 99·7 ± 2·9, after 10 mg kg−1 of losartan 89·9 ± 3·4, after 30 mg kg−1 of losartan 81·0 ± 2·9 mmHg). Conclusions Low doses of losartan reduce portal hypertension by an increase in splanchnic vascular resistance without hypotensive side‐effects on arterial pressure.Keywords
This publication has 31 references indexed in Scilit:
- Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHRBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2002
- Association of renal injury with nitric oxide deficiency in aged SHR: Prevention by hypertension control with AT1 blockadeKidney International, 2002
- Low dose losartan reduces portal pressure, improves kidney function and vascular contractility in cirrhotic rats without affecting arterial pressureJournal of Hepatology, 2002
- Effect of Losartan, An Angiotensin Ii Receptor Antagonist, on Portal Pressure in CirrhosisHepatology, 1999
- Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertensionPharmacology & Therapeutics, 1997
- Measurement of organ blood flow with coloured microspheres in the ratCardiovascular Research, 1995
- Role of bile acids in splanchnic hemodynamic response to chronic portal hypertensionDigestive Diseases and Sciences, 1991
- The Effect of the Combination of Nitroglycerin and Propranolol on Splanchnic and Systemic Hemodynamics in A Portal Hypertensive Rat ModelHepatology, 1985
- Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with CirrhosisNew England Journal of Medicine, 1981
- Effect of angiotensin‐ll blockade on systemic and hepatic haemodynamics and on the renin‐angiotensin‐aldosterone system in cirrhosis with ascitesEuropean Journal of Clinical Investigation, 1981